

## Urtoxazumab

Cat. No.:	HY-P99532
CAS No.:	502496-16-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Urtoxazumab (TMA-15) is a humanized monoclonal antibody against Shiga toxin (Stx) 2 <sup>[1]</sup> .	
In Vivo	Urtoxazumab (TMA-15) (0.25-2.5 mg/kg; i.v.; once) ameliorates the lethal challenge in a time- and dose- dependent manner in B2F1-infected mice <sup>[1]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	5-week-old male DBA/2J mice, STEC B2F1-infection model <sup>[1]</sup>
	Dosage:	0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg
	Administration:	Intravenous administration, 1 h before and 12, 24, and 48 h after infection
	Result:	Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.

### REFERENCES

[1]. Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA